Examining the effects of biofield therapy through simultaneous assessment of electrophysiological and cellular outcomes.

In this case study, a self-described biofield therapy (BT) practitioner (participant) took part in multiple (n = 60) treatment and control (non-treatment) sessions under double-blind conditions. During the treatment phases, the participant provided BT treatment at a distance of about 12 inches from the cells, alternating with rest phases where no such efforts were made. Human pancreatic cancer cell activity was assessed using three markers - cytoskeleton changes (tubulin and β-actin) and Ca uptake.